FDA approves Eversense Continuous Glucose Monitoring (CGM) System.-Senseonics Holdings.

Senseonics Holdings, Inc. announced the FDA has approved its Premarket Approval (PMA) application to market the company's Eversense Continuous Glucose Monitoring (CGM) System to people with diabetes in the United States. The system is the first and only CGM system to feature an implantable glucose sensor and provide long-term continuous monitoring for up to three months.

A significant number of people with diabetes do not use, or have access to, CGM .The Eversense System addresses many of the barriers to CGM use. The system consists of a fluorescence-based sensor, a smart transmitter worn over the sensor to facilitate data communication, and a mobile app for displaying glucose values, trends and alerts. The sensor, which is inserted subcutaneously in the upper arm by a physician via a brief in-office procedure, lasts up to three months, thereby eliminating the need for patients to self-administer the weekly or biweekly sensor insertions required by traditional CGM systems.